OPKO Health (OPK) Misses Q1 EPS by 18c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
OPKO Announces First Quarter Operating and Financial Results
May 11, 2015 4:00 PM EDTPfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015; OPKO Received $295 million of $570 Million Total Potential Pre-Commercialization Payments Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer RayaldeeTM New Drug Application (NDA) Submission Expected Later in May; Positive Rayaldee Phase 3 Clinical Trial Results Presented at the National Kidney Foundation Spring Clinical Meetings and 2015 ENDO Conference Investigational New Drug (IND) Application for Long Acting Factor VIIa-CTP for Hemophilia Accepted in Q1 2015; Phase 2a Clinical Trial to Commence in 1H 2015... More
